Página 1 dos resultados de 38 itens digitais encontrados em 0.003 segundos

Efeito do esteroide anabolico nandrolona sobre o nivel de ansidade em ratos; Anabolic steroids effects on anxiety level of rats

Vanessa de Moraes Rocha
Fonte: Biblioteca Digital da Unicamp Publicador: Biblioteca Digital da Unicamp
Tipo: Dissertação de Mestrado Formato: application/pdf
Publicado em 24/10/2006 PT
Relevância na Pesquisa
16.75%
Os esteróides androgênicos anabólicos (EAA) são usados no tratamento de hipogonadismo masculino, andropausa associada ao envelhecimento, osteoporose, anemia associada à doença renal crônica, síndrome de imunodeficiência adquirida, politraumatismo e em períodos pós-operatórios. Porém, o uso de EAA, com finalidades não?terapêuticas, e em altas doses, apresenta graves efeitos colaterais que incluem alterações de humor, agressividade e aumento da incidência de suicídios. O objetivo deste estudo foi avaliar o efeito do decanoato de nandrolona sobre o nível de ansiedade de ratos. Ratos machos Wistar, com 2 meses de idade foram aleatoriamente divididos em 6 grupos (n = 12- 15/grupo): controle, veículo, nandrolona, controle + diazepam, veículo + diazepam e nandrolona + diazepam. Animais tratados com veículo ou nandrolona receberam administração de propilenoglicol (0,2 mL/ Kg i.m.)ou decanoato de nandrolona (5mg/Kg i.m.), respectivamente, 2 vezes por semana, durante 6 semanas. Ratos do grupo controle foram submetidos somente aos procedimentos relacionados à rotina do biotério. No fim de 6 semanas, todos os grupos foram submetidos ao teste do LCE, 24 h após a última administração de veículo ou nandrolona, ou período equivalente para o grupo controle. Para validação farmacológica dos resultados comportamentais...

Laboratory Diagnosis of Late-Onset Male Hypogonadism Andropause

Clapauch, Ruth; Carmo, Aline Machado; Marinheiro, Lizanka Paola Figueiredo; Buksman, Salo; Pessoa, Isabel
Fonte: Sociedade Brasileira de Endocrinologia e Metabologia Publicador: Sociedade Brasileira de Endocrinologia e Metabologia
Tipo: Artigo de Revista Científica
EN
Relevância na Pesquisa
16.75%
Objetivos:Avaliar os fatores que influenciam o diagnóstico laboratorial do hipogonadismo masculino tardio. Métodos:Avaliamos 216 homens entre 52 e 84 anos. O diagnóstico laboratorial foi definido como dois valores de testos-terona livre calculada (TLC) <6,5 ng/dl, segundo a fórmula de Vermeulen, a partir das dosagens de testosterona total (TT), SHBG e albumina. Resultados: Na primeira dosagem, a TLC foi <6.5 ng/dl em 27% da amostra. Hipogonad-ismo laboratorial (confi rmado por duas dosagens) esteve presente em 19%, no entanto a TT foi baixa em apenas 4.1% dos homens. A idade influenciou a TT (p=0.0051) bem como o IMC; 23,5% dos homens ≥70 anos e 38,9% dos obesos com TT dentro dos níveis de referência eram, na verdade, hipogonádi-cos. Conclusão:Especialmente em homens obesos e nos ≥70 anos a dosa-gem de SHBG é importante para calcular TL e diagnosticar o hipogonadismo.

Risk of Late-Onset Hypogonadism (Andropause) in Brazilian Men over 50 Years of Age with Osteoporosis: Usefulness of Screening Questionnaires

Clapauch, Ruth; Braga, Daniel Jorge de Castro; Marinheiro, Lizanka Paola Figueiredo; Buksman, Salo; Schrank, Yolanda
Fonte: Sociedade Brasileira de Endocrinologia e Metabologia Publicador: Sociedade Brasileira de Endocrinologia e Metabologia
Tipo: Artigo de Revista Científica
EN
Relevância na Pesquisa
16.75%
Objetivos:Avaliar o risco relativo de hipogonadismo tardio em homens com osteoporose e a utilidade de questionários de triagem. Métodos:Correlacio-namos a pontuação dos questionários Aging Male’s Symptoms(AMS), An-drogen Deficiency of the Aging Male(ADAM) e International Index of Erectile Function(IIEF-5) com dosagens de testosteronas em 216 homens entre 50 e 84 anos (110 com osteoporose e 106 com densidade óssea normal, pareados por idade e etnia). Resultados:Hipogonadismo ocorreu em 25% dos osteo-poróticos e em 12,2% dos com densidade óssea normal (RR 2,08; IC95%: 1,14-3,79) e esteve associado à pergunta 1 do ADAM (diminuição de libido, p = 0,013). Testosterona total < 400 ng/dL associou-se a AMS > 26 (p = 0,0278). Disfunção erétil, avaliada pelo IIEF-5, não se correlacionou com dosagens de testosteronas. Conclusão:Hipogonadismo foi 2,08 vezes mais prevalente em homens com osteoporose e esteve associado à diminuição da libido (ADAM 1 positivo).

Diagnostic of andropause: a problem not yet solved

Casulari,Luiz Augusto; Motta,Lucilia D. Casulari da
Fonte: Sociedade Brasileira de Endocrinologia e Metabologia Publicador: Sociedade Brasileira de Endocrinologia e Metabologia
Tipo: Artigo de Revista Científica Formato: text/html
Publicado em 01/12/2008 EN
Relevância na Pesquisa
16.75%

Evaluation of late-onset hypogonadism (andropause) treatment using three different formulations of injectable testosterone

Hohl,Alexandre; Marques,Mario Octávio Thá; Coral,Marisa Helena César; Walz,Roger
Fonte: Sociedade Brasileira de Endocrinologia e Metabologia Publicador: Sociedade Brasileira de Endocrinologia e Metabologia
Tipo: Artigo de Revista Científica Formato: text/html
Publicado em 01/11/2009 EN
Relevância na Pesquisa
27.41%
OBJECTIVE: To compare the modalities of treatment for male hypogonadism available in Brazil. METHODS: Thirty-two men with late-onset hypogonadism ("andropause") were followed-up in the Hospital de Guarnição de Florianópolis, in Florianópolis, south Brazil. Clinical diagnosis was established according to AMS questionnaire (positive if equal to or higher than 27 points), and laboratorial diagnosis was made through low values of total testosterone (under 300 ng/dL) and/or free calculated testosterone (under 6.5 ng/dL). Patients were randomized to three non-enteral treatment groups (Deposteron® - 11 patients; Durateston® - 11 patients; and Nebido® - 10 patients). RESULTS: Clinically, Nebido® seemed to be superior when compared to Deposteron® (mean value of improvement percentage; p = 0.03) and when compared to Durateston® (post-treatment average AMS score; p = 0.03). According to laboratorial analysis, Nebido® showed higher testosterone levels than Deposteron® and Durateston® (p < 0.001). CONCLUSIONS: All non-enteral testosterone formulas available in the Brazilian market are efficient in raising testosterone levels and in clinical improvement of hypogonadal patients. Nebido® showed both a better clinical and laboratorial effectiveness.

Short term testosterone replacement therapy improves libido and body composition

Andrade Júnior,Edésio Seara de; Clapauch,Ruth; Buksman,Salo
Fonte: Sociedade Brasileira de Endocrinologia e Metabologia Publicador: Sociedade Brasileira de Endocrinologia e Metabologia
Tipo: Artigo de Revista Científica Formato: text/html
Publicado em 01/11/2009 EN
Relevância na Pesquisa
16.75%
OBJECTIVE: To assess the efficacy and safety of testosterone replacement in males with late-onset hypogonadism compared to hypogonadal men without replacement, and controls, during six months. METHODS: We assessed, through ADAM, AMS, IIEF-5 and SF-36 questionnaires, and through clinical and laboratorial examinations, 62 patients divided into three groups: 17 hypogonadal males (HR) used intramuscular testosterone every three weeks; 14 hypogonadal males (HV) and 31 non-hypogonadal males (CV) used oral vitamins daily. RESULTS: When compared to others, HR group obtained libido improvement assessed by ADAM 1 (p = 0.004), and borderline sexual potency improvement assessed by IIEF-5 (p = 0.053), besides a decrease in waist circumference after eight weeks (p = 0.018). The remaining parameters did not differ between the groups. PSA and hematocrit remained stable in those using testosterone. CONCLUSION: Six months of testosterone replacement improved sexuality and body composition, with prostatic and hematological safety.

Summary of the American College for Advancement in Medicine May 2005 Conference: Menopause, Andropause: Power in Transition

Feig, Stephen A.; Hynote, Eleanor; Speight, Neal; Magaziner, Allan; Miranda, Ralph A.; Schachter, Michael B
Fonte: Oxford University Press Publicador: Oxford University Press
Tipo: Artigo de Revista Científica
Publicado em /09/2005 EN
Relevância na Pesquisa
16.75%

Testosterone Replacement in Men with Andropause: An Overview

Brawer, Michael K
Fonte: MedReviews, LLC Publicador: MedReviews, LLC
Tipo: Artigo de Revista Científica
Publicado em //2004 EN
Relevância na Pesquisa
27.41%
Serum testosterone levels decline progressively as men age, with resulting pathophysiological changes. Because the onset of andropause is gradual and many of its symptoms mirror those associated with medications or disease states common in the elderly, a clinical diagnosis can be difficult to make. Additionally, because of a lack of established normal testosterone levels for different age groups, as well as confusion regarding what subset of testosterone to measure, simply testing testosterone levels is inadequate. Although clinical studies have shown testosterone supplementation to be safe, no long-term placebo-controlled trials have been performed. Among the possible side effects of testosterone replacement therapy is an increased risk of prostate cancer. While there is no evidence that supplemental testosterone will initiate prostate cancer or cause clinically significant progression of an established occult malignancy, the initial evaluation of patients prior to administration of testosterone requires screening for prostatic carcinoma. A number of formulations of testosterone are currently available; transdermal gels, although expensive, are the preferred modality because of their ease of administration.

Testosterone Replacement Therapy for a Man with Prostate Cancer

Brawer, Michael K
Fonte: MedReviews, LLC Publicador: MedReviews, LLC
Tipo: Artigo de Revista Científica
Publicado em //2004 EN
Relevância na Pesquisa
16.75%
A 52-year-old male with elevated serum prostate-specific antigen (PSA) level, moderate lower urinary tract symptoms (LUTS), and negative family history of prostate cancer is found to have adenocarcinoma of the prostate with negative bone scan. Following radical retropubic prostatectomy and satisfactory postoperative recovery, heretofore undetectable serum PSA level rose 35 months later. Digital rectal examination (DRE) and bone scan were negative. Adjuvant external beam radiation preceded by a 3-month injection of goserelin was initiated. Radiation was well tolerated, although the patient reported significant loss of libido, hot flashes, and depression warranting antidepressant medication. Failure to respond to this intervention led to initiation of supplemental testosterone; 1 month later, the patient reported significant relief of symptoms. The patient is currently successfully tapering use of supplemental testosterone in order to decrease andropause symptoms and to permit restoration of intrinsic testosterone.

Rising PSA during Testosterone Replacement Therapy

Gore, John; Rajfer, Jacob
Fonte: MedReviews, LLC Publicador: MedReviews, LLC
Tipo: Artigo de Revista Científica
Publicado em //2004 EN
Relevância na Pesquisa
17.41%
Although testosterone replacement therapy (TRT) is indicated for the management of symptomatic hypogonadism, there is still controversy over whether TRT should be administered to middle-aged men for the clinical manifestations of andropause, regardless of whether the serum testosterone levels are depressed or not. Side effects of TRT may include fluid retention, gynecomastia, polycythemia, and exacerbation of existing prostate cancer. As a result, patients on TRT require meticulous surveillance including regular digital rectal examination and serum prostate-specific antigen (PSA) testing. Herein, we present the case of a middle-aged man with andropause and a rising PSA on TRT.

Hormone Treatments and Preventive Strategies in the Aging Male: Whom and When to Treat?

Heaton, Jeremy PW
Fonte: MedReviews, LLC Publicador: MedReviews, LLC
Tipo: Artigo de Revista Científica
Publicado em //2003 EN
Relevância na Pesquisa
17.96%
Sex hormones have a broad range of actions in regulating very diverse systems throughout life. Testosterone and other related hormones change with age to varying degrees and may induce pathophysiological changes and the clinical condition known as andropause. Androgen replacement is the accepted but not the only possible treatment for andropause. The presence of clinical symptoms, including a loss of sexual function, intellectual capacity, lean body mass, or bone mineral density; alterations in body hair, skin, or sleep pattern; or increases in visceral fat, together with low levels of serum testosterone characterize andropause. An appreciation of the potentially undesirable impact of androgens on the biology of prostate cancer, as well as possibly the cardiovascular system, is necessary. However, proper evaluation of aging men with symptoms of andropause will result in a decision to initiate androgen therapy in some aging men.

Andropause. Testosterone replacement therapy for aging men.

Bain, J.
Fonte: PubMed Publicador: PubMed
Tipo: Artigo de Revista Científica
Publicado em /01/2001 EN
Relevância na Pesquisa
27.41%
OBJECTIVE: To review the rationale for treating symptomatic aging men whose testosterone levels are mildly reduced or low-normal with testosterone replacement therapy. QUALITY OF EVIDENCE: Large-scale multicentre prospective studies on the value of treating andropausal men with hormone therapy do not exist because the whole area of hormone therapy is barely 10 years old. Evidence presented is based on physiologic studies, particularly studies in which treatment has been assessed. These were largely uncontrolled open studies. Studies to date report positive responses to testosterone treatment with very few serious side effects. MAIN MESSAGE: Physicians should consider hypoandrogenism if male patients complain of loss of libido, erectile dysfunction, weakness, fatigue, lethargy, loss of motivation, or mood swings. Less obvious associations with reduced levels of testosterone are anemia and osteoporosis. The main cause of reduced testosterone production is primary gonadal insufficiency, but secondary causes, such as hypothalamic-pituitary disease, should be considered. Evidence shows that most men treated with testosterone will feel better about themselves and their lives. CONCLUSION: Andropause is a term of convenience describing a complex of symptoms in aging men who have low testosterone levels. Physicians should be aware of its existence...

The andropause: fact or fiction?

Burns-Cox, N.; Gingell, C.
Fonte: BMJ Group Publicador: BMJ Group
Tipo: Artigo de Revista Científica
Publicado em /09/1997 EN
Relevância na Pesquisa
27.96%
The so-called andropause is an ill-defined collection of symptoms in a group of men who may have low but may also have normal androgen levels. Unlike the proven benefits of hormone replacement therapy in women, the effects of testosterone supplementation in men are equivocal. It may increase sexual interest, but rarely to a level thought adequate by the patient. It has no proven beneficial effect on erectile dysfunction and other possible beneficial effects on haemopoesis, bone metabolism, lipids and fibrinolysis have yet to be demonstrated. With the availability of the testosterone patch, sustained increases in the serum testosterone levels will be readily achieved and could theoretically significantly affect the behaviour of subclinical prostate cancer. At the present time, testosterone replacement therapy in hypogonadal men is of proven clinical benefit; this is not the case, however, for eugonadal men with symptoms attributed to the andropause. The symptoms of the andropause fatigue can readily be explained by stress and there is no scientifically valid, placebo-controlled study that shows any benefit for testosterone supplements in this not uncommon group of patients.

Andropause and the development of cardiovascular disease presentation—more than an epi-phenomenon

Schwarz, Ernst R.; Phan, Anita; Willix, Robert D.
Fonte: Science Press Publicador: Science Press
Tipo: Artigo de Revista Científica
Publicado em /03/2011 EN
Relevância na Pesquisa
27.75%
Andropause refers to a generalized decline of male hormones, including testosterone and dehydroepiandrosterone in middle-aged and aging men. This decline in hormones has been associated with changes such as depression, loss of libido, sexual dysfunction, and changes in body composition. Aging has been associated with an abundance of concomitant diseases, in particular cardiovascular diseases, and although andropause is correlated to aging, a causal relationship between reduction of androgens and the development of chronic diseases such as atherosclerosis and heart failure has not been convincingly established yet. On the other hand, increasing data has emerged that revealed the effects of low levels of androgens on cardiovascular disease progression. As an example, low levels of testosterone have been linked to a higher incidence of coronary artery disease. Whether hormone replacement therapy that is used for andropausal men to alleviate symptoms of “male menopause” can halt progression of cardiovascular disease, remains controversially discussed, primarily due to the lack of well-designed, randomized controlled trials. At least for symptom improvement, the use of androgen replacement therapy in andropausal men may be clinically indicated...

Andropause: Current concepts

Singh, Parminder
Fonte: Medknow Publications & Media Pvt Ltd Publicador: Medknow Publications & Media Pvt Ltd
Tipo: Artigo de Revista Científica
Publicado em /12/2013 EN
Relevância na Pesquisa
27.41%
Andropause or late-onset hypogonadism is a common disorder which increases in prevalence with advancing age. Diagnosis of late-onset of hypogonadism is based on presence of symptoms suggestive of testosterone deficiency - prominent among them are sexual symptoms like loss of libido, morning penile erection and erectile dysfunction; and demonstration of low testosterone levels. Adequate therapeutic modalities are currently available, but disparate results of clinical trial suggest further evaluation of complex interaction between androgen deficiency and ageing. Before initiating therapy benefits and risk should be discussed with patients and in case of poor response, alternative cause should be investigated.

Oxytocin Reverses Osteoporosis in a Sex-Dependent Manner

Beranger, Guillaume E.; Djedaini, Mansour; Battaglia, Séverine; Roux, Christian H.; Scheideler, Marcel; Heymann, Dominique; Amri, Ez-Zoubir; Pisani, Didier F.
Fonte: Frontiers Media S.A. Publicador: Frontiers Media S.A.
Tipo: Artigo de Revista Científica
Publicado em 19/05/2015 EN
Relevância na Pesquisa
17.41%
The increase of life expectancy has led to the increase of age-related diseases such as osteoporosis. Osteoporosis is characterized by bone weakening promoting the occurrence of fractures with defective bone regeneration. Men aged over 50 have a prevalence for osteoporosis of 20%, which is related to a decline in sex hormones occurring during andropause or surgical orchidectomy. As we previously demonstrated in a mouse model for menopause in women that treatment with the neurohypophyseal peptide hormone oxytocin (OT) normalizes body weight and prevents the development of osteoporosis, herein we addressed the effects of OT in male osteoporosis. Thus, we treated orchidectomized mice, an animal model suitable for the study of male osteoporosis, for 8 weeks with OT and then analyzed trabecular and cortical bone parameters as well as fat mass using micro-computed tomography. Orchidectomized mice displayed severe bone loss, muscle atrophy accompanied by fat mass gain as expected in andropause. Interestingly, OT treatment in male mice normalized fat mass as it did in female mice. However, although OT treatment led to a normalization of bone parameters in ovariectomized mice, this did not happen in orchidectomized mice. Moreover, loss of muscle mass was not reversed in orchidectomized mice upon OT treatment. All of these observations indicate that OT acts on fat physiology in both sexes...

Andropause: A quality-of-life issue in older males

Haren, M.; Kim, M.; Tariq, S.; Wittert, G.; Morley, J.
Fonte: W B Saunders Co Publicador: W B Saunders Co
Tipo: Artigo de Revista Científica
Publicado em //2006 EN
Relevância na Pesquisa
27.41%
Testosterone deficiency occurs commonly in men as they grow older. This deficiency often is associated with a decline in sexual activity and a loss of muscle mass. Testosterone replacement can reverse many of these effects. At present, no ideal form of testosterone replacement is available. Like the phosphodiesterase-5 inhibitors, testosterone replacement in older men is a quality of life issue.; Matthew T. Haren, Moon Jong Kim, Syed H. Tariq, Gary A. Wittert, John E. Morley; Copyright © 2006 Elsevier Inc. All rights reserved.

Laboratory diagnosis of late-onset male hypogonadism andropause

Clapauch,Ruth; Carmo,Aline Machado; Marinheiro,Lizanka; Buksman,Salo; Pessoa,Isabel
Fonte: Sociedade Brasileira de Endocrinologia e Metabologia Publicador: Sociedade Brasileira de Endocrinologia e Metabologia
Tipo: Artigo de Revista Científica Formato: text/html
Publicado em 01/12/2008 EN
Relevância na Pesquisa
27.41%
OBJECTIVES: To evaluate which factors influence the laboratorial diagnosis of late-onset male hypogonadism (LOH). METHODS: Total testosterone (TT), SHBG and albumin were measured in 216 men aged 52-84 years. The laboratorial definition of LOH was two values of calculated free testosterone (cFT) <6.5 ng/dl, according to Vermeulen's formula. RESULTS: At the first blood test, cFT was <6.5 ng/dl in 27% of the men. Laboratorial LOH (confirmed by two tests) was present in 19%, but TT levels were low in only 4.1%. Age influenced TT (p=0.0051) as well as BMI; 23.5% of patients > 70 years and 38.9% of the obese men who had TT within the reference range were, in fact, hypogonadal. CONCLUSION: Especially in obese men and in those > 70 years old, SHBG dosage is important to calculate FT levels and diagnose hypogonadism.

Risk of late-onset hypogonadism (andropause) in Brazilian men over 50 years of age with osteoporosis: usefulness of screening questionnaires

Clapauch,Ruth; Braga,Daniel Jorge de Castro; Marinheiro,Lizanka Paola; Buksman,Salo; Schrank,Yolanda
Fonte: Sociedade Brasileira de Endocrinologia e Metabologia Publicador: Sociedade Brasileira de Endocrinologia e Metabologia
Tipo: Artigo de Revista Científica Formato: text/html
Publicado em 01/12/2008 EN
Relevância na Pesquisa
27.41%
OBJECTIVE: To analyze the relative risk of late-onset hypogonadism in men with osteoporosis and the usefulness of screening questionnaires. METHODS: We correlated the Aging Male's Symptoms (AMS), Androgen Deficiency in Aging Male (ADAM) and International Index of Erectile Function (IIEF-5) questionnaires and the laboratory diagnosis of hypogonadism in 216 men aged 50-84 years (110 with osteoporosis and 106 with normal bone density, paired by age and ethnicity). RESULTS: Hypogonadism presented in 25% of the osteoporotic and in 12.2 % of normal bone density men (OR 2.08; IC95%: 1.14-3.79) and was associated with ADAM first question (low libido, p=0.013). Levels of TT below 400 ng/dl correlated with an AMS score above 26 (p=0.0278). IIEF-5 showed no correlation with testosterone levels. CONCLUSION: Hypogonadism was 2.08 times more prevalent in osteoporotic men. The symptom that best correlated with late-onset hypogonadism was low libido (ADAM 1 positive).

Improvement of andropause symptoms by dandelion and rooibos extract complex CRS-10 in aging male

Noh, Yoo-Hun; Kim, Do-Hee; Kim, Joon Yub; Park, Jiae; Kim, Ok Hyeon; Han, Daeseok; Kim, Won-Yong; Kim, Sung-Su; Lee, Moo-Yeol; Heo, Seok-Hyun; Kim, Misook; Lee, Won Bok; Jeong, Yoonhwa; Myung, Soon Chul
Fonte: The Korean Nutrition Society and the Korean Society of Community Nutrition Publicador: The Korean Nutrition Society and the Korean Society of Community Nutrition
Tipo: Artigo de Revista Científica
EN
Relevância na Pesquisa
27.96%
Many aging male suffer various andropause symptoms including loss of physical and mental activities. This study evaluated the putative alleviative effects of CRS-10 dandelion and rooibos extract complex (CRS-10) on the symptoms of andropause. The survival rate of TM3 Leydig cells (TM3 cells) treated with CRS-10 was measured based on typical physiological stress. After daily intake of CRS-10 for 4 weeks, the level of testosterone, physical activity and both the number and activity of sperm in older rats (18 weeks) were measured. Furthermore, thirty males were surveyed with AMS (Aging Males' Symptoms) questionnaire after intake of 400 mg of CRS-10. Overall, CRS-10 protected TM3 cells from serum restriction and oxidative stress via activation of ERK and Akt pathways. The level of testosterone and activation of spermatogenesis in rats were significantly enhanced. In addition, physical locomotion was markedly improved. Daily intake of 400 mg of CRS-10 improved the quality of life among agingmale respondents, according to a clinical survey using the AMS. The results indicate the potential of CRS-10 as a safe and efficacious natural substance for reducing or alleviating andropause symptoms.